Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Susan M Domchek"'
Autor:
Shannon Gallagher, Jeffrey N. Weitzel, Eric Rosenthal, Placede Tshiaba, Danna F. Grear, Jerry S. Lanchbury, Judy Garber, Susanne Wagner, Benjamin B. Roa, Wade Hedegard, Kathryn Dalton, Mark E. Robson, Johnathan M. Lancaster, Alexander Gutin, Allison W. Kurian, Susan M. Domchek, Elisha Hughes, Thaddeus Judkins, Carol A. Adami, Stephanie Meek
Publikováno v:
JCO Precision Oncology
PURPOSE Screening and prevention decisions for women at increased risk of developing breast cancer depend on genetic and clinical factors to estimate risk and select appropriate interventions. Integration of polygenic risk into clinical breast cancer
Autor:
Elisha Hughes, Susanne Wagner, Dmitry Pruss, Ryan Bernhisel, Braden Probst, Victor Abkevich, Timothy Simmons, Brooke Hullinger, Thaddeus Judkins, Eric Rosenthal, Benjamin Roa, Susan M. Domchek, Charis Eng, Judy Garber, Monique Gary, Jennifer Klemp, Semanti Mukherjee, Kenneth Offit, Olufunmilayo I. Olopade, Joseph Vijai, Jeffrey N. Weitzel, Pat Whitworth, Lamis Yehia, Ora Gordon, Holly Pederson, Allison Kurian, Thomas P. Slavin, Alexander Gutin, Jerry S. Lanchbury
Publikováno v:
JCO Precision Oncology.
PURPOSE Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. Their application to women of non-European ancestry has lagged because of the lack of a formal approach to in
Autor:
Shannon Gallagher, Johnathan M. Lancaster, Judy Garber, Jerry S. Lanchbury, Eric Rosenthal, Mark E. Robson, Susan M. Domchek, Alexander Gutin, Allison W. Kurian, Thaddeus Judkins, Benjamin B. Roa, Placede Tshiaba, Susanne Wagner, Jeffrey N. Weitzel, Elisha Hughes
Publikováno v:
JCO Precision Oncology
PURPOSE Women with a family history of breast cancer are frequently referred for hereditary cancer genetic testing, yet < 10% are found to have pathogenic variants in known breast cancer susceptibility genes. Large-scale genotyping studies have ident
Autor:
Kim A, Reiss, Shun, Yu, Renae, Judy, Heather, Symecko, Katherine L, Nathanson, Susan M, Domchek
Publikováno v:
JCO precision oncology. 2
Germline mutations in the homologous recombination (HR) genesTwenty-nine individuals with deleterious germline mutations inPatients who were mut-positive had an OS of 21.8 months; control patients had an OS of 8.1 months (hazard ratio [HR], 0.35; 95%
Autor:
Shun, Yu, Parul, Agarwal, Ronac, Mamtani, Heather, Symecko, Kelsey, Spielman, Mark, O'Hara, Peter J, O'Dwyer, Charles, Schneider, Ursina, Teitelbaum, Katherine L, Nathanson, Susan M, Domchek, Kim A, Reiss
Publikováno v:
JCO precision oncology. 3
Germline mutations in the homologous recombination genesThirty-two individuals with pathogenic germline mutations inPatients in the mutation-positive group had a median OS (mOS) of 46.6 months; those in the mutation-negative group had an mOS of 23.2
Autor:
Shun Yu, Parul Agarwal, Ronac Mamtani, Heather Symecko, Kelsey Spielman, Mark O’Hara, Peter J. O’Dwyer, Charles Schneider, Ursina Teitelbaum, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss
Publikováno v:
JCO Precision Oncology. :1-11
PURPOSE Germline mutations in the homologous recombination genes BRCA1, BRCA2, and PALB2 confer an increased risk for pancreatic ductal adenocarcinoma (PDAC). Tumors associated with mutations in homologous recombination genes are sensitive to DNA-dam
Autor:
Eric Rosenthal, Benjamin B. Roa, Thomas P. Slavin, Susan M. Domchek, Alexander Gutin, Allison W. Kurian, Mark E. Robson, Brian Morris, Stephanie Meek, Susanne Wagner, Jeffrey N. Weitzel, Judy Garber, Placede Tshiaba, Shannon Gallagher, Braden Probst, Jerry S. Lanchbury, Elisha Hughes
Publikováno v:
JCO Precision Oncology
PURPOSE Breast cancer risks for CHEK2 and ATM pathogenic variant (PV) carriers are modified by an 86-single nucleotide polymorphism polygenic risk score (PRS) and individual clinical factors. Here, we describe comprehensive risk prediction models for
Autor:
Susan M. Domchek, Rachna T. Shroff, Kevin K. Lin, Andrew Eugene Hendifar, Ron Epelbaum, Heidi Giordano, Ravit Geva, Robert H. Vonderheide, Sandra Goble, Andrew V. Biankin, Lindsey Rolfe, Robert R. McWilliams
Publikováno v:
JCO precision oncology, vol 2018, iss 2
Purpose Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 ( BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant act
Publikováno v:
JCO Precision Oncology. :1-9
Purpose Germline mutations in the homologous recombination (HR) genes BRCA1, BRCA2, and PALB2 confer an increased risk for pancreatic ductal adenocarcinoma (PDAC). Tumors associated with mutations in HR genes are sensitive to DNA-damaging agents, suc
Autor:
Michelle Savage, Sarah M. Nielsen, Janice Horte, Michael J. Hall, Susan Montgomery, Kristin Mattie, Amanda Brandt, Cassandra Gulden, Jessica Stoll, Susan M. Domchek, Christina Seelaus, Rachelle Chambers, Angela R. Bradbury, Mary B. Daly, Shreshtha Madaan, Dana F Clark, Brian L. Egleston, Rikki Gaber, Generosa Grana, Kim Rainey, Pamela S. Ganschow, Xinxin Shirley Yao, Jessica M. Long, Olufunmilayo I. Olopade, Jill Stopfer, Christina Rybak, Danielle McKenna, Linda Patrick-Miller, Terra Lucas, Jacquelyn Powers, Dominique Fetzer, Andrea Forman
Publikováno v:
JCO Precision Oncology. :1-12
Purpose Multigene panels (MGPs) are increasingly being used despite questions regarding their clinical utility and no standard approach to genetic counseling. How frequently genetic providers use MGP testing and how patient-reported outcomes (PROs) d